Structure Therapeutics Inc. - GPCR Total Company Value-to-Revenue Ratio

Structure Therapeutics Inc (GPCR) - corporate logo

The change in the EV/Sales multiple demonstrates the valuation dynamics of Structure Therapeutics (GPCR), where 0.00 expresses the current value of the metric. Share prices depend on the results of new drug trials rather than fundamentals. Production is based on outsourcing via CMO plants. High confidence within the scientific community regarding innovations in the fight against obesity fosters a positive brand image.

GPCR Structure Therapeutics: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/19/2026

Financial and market metric breakdowns for Structure Therapeutics Inc. (GPCR)

Initial company analysis:Structure Therapeutics Inc. GPCR
Original product of structuretx.com

The metric is calculated as the ratio of total enterprise value, including debt and cash, to annual sales volume. This metric determines the market value of each dollar of revenue, ignoring financing specifics. For Structure Therapeutics (GPCR), the calculation reflects inflated expectations for future anti-obesity drugs. The current business does not yet generate commercial revenue, making the EV/Sales valuation an indicator of a speculative premium. The trend in this EV/Sales valuation illustrates the market's willingness to pay a premium for the potential success of clinical trials.

Direct competitors

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|MDXG (MiMedx Corp) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Rezolute Inc RZLT|EV/Sales Multiple LXRX|Total Company Value-to-Revenue Ratio MBX Corp|Altimmune Pharma - Company Value to Revenue|EV/Sales Multiple aardvarktherapeutics.com AARD|SGMT: Company Value to Revenue|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)